Modeling Huntington's disease in cells, flies, and mice

Molecular Neurobiology

Volumn 23, Issue 1, 2001, Pages 21-51

  Sipione, S ^a   Cattaneo, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoptosis; Caspases; Huntingtin; Huntington's Disease; Models

Indexed keywords

CASPASE; HUNTINGTIN; MUTANT PROTEIN;

ANIMAL MODEL; APOPTOSIS; CELL LINE; CELL SURVIVAL; CLINICAL FEATURE; CYTOLOGY; DISEASE MODEL; FLY; GENE EXPRESSION REGULATION; GENETICS; HUNTINGTON CHOREA; INTRACELLULAR TRANSPORT; KNOCKOUT GENE; MEMBRANE VESICLE; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; WORM;

EID: 0034791680     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:23:1:21     Document Type: Review

References (193)

1. Huntington disease: Clinical, genetic, and social aspects
2. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size
3. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control
4. Body weight and dietary factors in Huntington's disease patients compared with matched controls
5. Characteristics of individuals with Huntington disease in long-term care
6. Higher sedentary energy expenditure in patients with Huntington's disease
7. Weight loss in Huntington's disease
8. Juvenile Huntington disease
9. The neurobiology of Huntington's disease
10. Differential loss of striatal projection neurons in Huntington disease
11. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease
12. Preferential loss of striatoexternal pallidal projection neurons in presymptomatic Huntington's disease
13. Morphometric analysis of the prefrontal cortex in Huntington's disease
14. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease
15. Huntington's disease
16. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy
17. A polymorphic DNA marker genetically linked to Huntington's disease
18. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome
19. CAG repeat size and clinical presentation in Huntington's disease
20. Molecular genetics of Huntington's disease
21. Trinucleotide repeat length and clinical progression in Huntington's disease
22. Instability of CAG repeats in Huntington's disease: Relation to parental transmission and age of onset
23. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease
24. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease
25. Genetic polymorphisms adjacent to the CAG repeat influence clinical features at onset in Huntington's disease
26. Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number
27. A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: Implications for diagnostic accuracy and predictive testing
28. Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: Insights into the genetic evolution of Huntington disease
29. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease
30. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD
31. Loss of normal huntingtin function: New developments in Huntington's disease research
32. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease
33. A single allele from the polymorphic CCG rich sequence immediately 3′ to the unstable CAG trinucleotide in the IT15 cDNA shows almost complete disequilibrium with Huntington's disease chromosomes in the Scottish population
34. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence
35. Unstable triplet repeat diseases
36. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain
37. Dramatic mutation instability in HD mouse striatum: Does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease
38. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation
39. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form
40. Huntingtin localization in brains of normal and Huntington's disease patients
41. Huntington's disease gene (IT15) is widely expressed in human and rat tissues
42. Huntingtin is a cytoplasmic protein associated with vescicles in human an rat brain neurons
43. Widespread expression of Huntington's disease gene (IT15) protein product
44. Expression of normal and mutant huntigtin in the developing brain
45. Differential distribution of the normal and mutated forms of huntingtin in the human brain
46. Cellular localization of huntingtin in striatal and cortical neurons in rat: Lack correlation of with neuronal vulnerability in Huntington disease
47. Neurobiology of Huntington's disease
48. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
49. Differential 3′ polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression
50. Expression of the Huntington disease gene in rodents: Cloning the rat homologue and evidence for downregulation in non-neuronal tissues during development
51. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues
52. mRNAs encoding a von Ebner's-like protein and the Huntington disease protein are induced in rat male germ cells by Sertoli cells
53. Structural analysis of the 5′ region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms
54. Isolation and characterization of the rat huntingtin promoter
55. DNA-binding properties of the product of the testis-determining gene and a related protein
56. DNA binding activity of recombinant SRY from normal males and XY females
57. Analysis of the 5′ upstream sequence of the Huntington's disease (HD) gene shows six new rare alleles which are unrelated to the age at onset of HD
58. 12-O-tetradecanoyl-phorbol-13-acetate down-regulates the huntingtin promoter at Spl sites
59. Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats
60. Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles
61. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain
62. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid
63. Excitotoxin lesions in primates as a model for Huntington's disease: Histopathologic and neurochemical characterization
64. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
65. Replicating Huntington's disease phenotype in experimental animals
66. Inactivation of the mouse Huntington's disease gene homolog Hdh
67. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes
68. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue
69. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues
70. Neuronal degeneration in the basal ganglia andloss of pallido subthalamic synapses in mice with targeted disruption of the Huntington's disease gene
71. Life without huntingtin: Normal differentiation into functional neurons
72. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
73. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knock-in mouse models of Huntington's disease
74. Huntingtin is required for normal hematopoiesis
75. Huntingtin is required for neurogenesis and is not impaired by Huntington's disease CAG expansion
76. Inactivation of hdh in the brain and testis results in progressive neurodegeneration and sterility in mice
77. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo
78. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
79. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene
80. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease
81. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation
82. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes
83. Formation of polyglutamine inclusions in non-CNS tissue
84. Diabetes mellitus in Huntington disease
85. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
86. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
87. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
88. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
89. Huntington's disease. In reverse gear
90. Reversing neurodegeneration: A promise unfolds
91. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse
92. Fourteen and counting: Unraveling trinucleotide repeat diseases
93. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated fulllength HD cDNA
94. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
95. Of mice and men: Solving the molecular mysteries of Huntington's disease
96. Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse
97. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice
98. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
99. Neurological abnormalities in a knock-in mouse model of Huntington's disease
100. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila
101. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons
102. Genetic suppression of polyglutamine toxicity in Drosophila
103. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron
104. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
105. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture
106. The influence of huntingtin protein size on nuclear localization and cellular toxicity
107. Expression of polyglutamine-expanded huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line
108. Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin
109. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
110. Immortalized murine striatal neuronal cell lines expressing dopamine receptors and cholinergic properties
111. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
112. Generation of neuronal intranuclear inclusions by polyglutamine-GFP: Analysis of inclusion clearance and toxicity as a function of polyglutamine length
113. Caspase-8 is required for cell death induced by expanded polyglutamine repeats
114. Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin
115. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor
116. A cellular model that recapitulates major pathogenic steps of Huntington's disease
117. A short term analysis of the behaviour of conditionally immortalized neuronal progenitors and primary neuroepithelial cells implanted into the fetal rat brain
118. Activation of the JAK/STAT pathway leads to proliferation of ST14A central nervous system progenitor cells
119. Generation and characterization of embryonic striatal conditionally immortalized ST14A cells
120. Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum
121. Gene therapy of experimental brain tumors using neural progenitor cells
122. Wildtype huntingtin protects from apoptosis upstream of caspase-3
123. ST14A cells have properties of a medium size spiny neuron
124. Aberrant amplification of A2A receptor signalling in striatal cells expressing mutant huntingtin
125. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
126. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
127. Dominant phenotypes produced by the HD mutation in STHdh (Q111) striatal cells
128. Polyglutamine diseases: Protein cleavage and aggregation
129. Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases
130. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: Relevance to diseases of the nervous system
131. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
132. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
133. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
134. Transgenic mice expressing mutated full-length HD cDNA: A paradigm for locomotor changes and selective neuronal loss in Huntington's disease
135. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases
136. Nuclear inclusion in glutamine repeat disorders: Are they pernicious, coincidental, or beneficial?
137. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease
138. Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease
139. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: Their role in suppression of aggregation and cellular toxicity
140. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease
141. Role of Hsp70 in regulation of stress-kinase JNK: Implications in apoptosis and aging
142. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening
143. Aggregates in neurodegenerative disease: Crowds and power
144. A huntingtin-associated protein enriched in brain with implications for pathology
145. HIP-1 a huntingtin interacting protein isolated by the yeast two hybrid system
146. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain
147. SH3GL3 associates with the huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates
148. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain
149. Expression of huntingtin-associated protein-1 in neuronal cells implicates a role in neurite growth
150. HAP1-huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice
151. Huntingtin interacts with a family of WW domain proteins
152. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin
153. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
154. Towards prediction of cognate complexes between the WW domain and proline-rich ligands
155. Characterization of a novel protein-binding module: The WW domain
156. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complex
157. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin
158. Huntingtin interacts with cystathionine β-synthase
159. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH
160. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme
161. Isolation of a 40 kDa huntingtin-associated protein
162. Energetics in the pathogenesis of neurodegenerative diseases
163. Transcriptional dysregulation in Huntington's disease
164. Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways
165. Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin
166. Fast transport and retrograde movement of huntingtin and HAP 1 in axons
167. Polyglutamine-induced ion channels: A possible mechanism for the neurotoxicity of Huntington and other CAG repeat diseases
168. Huntingtin expression stimulates endosomallysosomal activity, endosome tubulation, and autophagy
169. Transcriptional activation modulated by homopolymeric glutamine and proline stretches
170. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis
171. HEAT repeats in the Huntington's disease protein
172. Structural view of the Ran-Importin beta interaction at 2.3 A resolution
173. The identification of a functional nuclear localization signal in the Huntington disease protein
174. Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis
175. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
176. Inhibition of ICE slows ALS in mice
177. Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein
178. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
179. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
180. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
181. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells
182. Expression of extended polyglutamine sequentially activates initiator and effector caspases
183. Activation of G1 progression, JNK mitogen-activated protein kinase, and actin filament assembly by the exchange factor FGD1
184. Mitogen-activated protein kinase 7 is an activator of the c- Jun NH2-terminal kinase
185. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
186. The mitochondrial permeability transition in Huntington's Disease
187. A one-hit model of cell death in inherited neuronal degenerations
188. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington's disease
189. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
190. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity